

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60534</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Targeted Overexpression of NDRG2 using Survivin Promoter Reduces Viability and  Invasiveness of A549 Cell Line</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Fanian</surname><given-names>Maryam</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rafiei </surname><given-names>Gholamreza</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Alizadeh Zarei</surname><given-names>Marzieh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Takhshid</surname><given-names>Mohammad Ali</given-names></name></contrib><aff>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>15</volume>
      <issue>2</issue>
      <fpage>84</fpage>
      <lpage>90</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>7</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:13pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Background: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Anti-tumor effects of N-myc Downstream Regulated Gene2 (NDRG2) have been demonstrated in many tumors. In the present study, NDRG2 was specifically overexpressed in lung cancer cell line using Survivin Promoter (Sur-P). Then, the effects of NDRG2 overexpression on viability, apoptosis, migration, and invasion of A549 cells were evaluated.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:13pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Recombinant &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;pAdenoVator-&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Sur-P&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;-NDRG2-IRES-GFP&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;plasmid&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; harboring &lt;/span&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;NDRG2&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; gene under transcriptional control of Sur-P and mock plasmid were constructed. A549 lung tumor cells and LX-2 cells (non-tumor cell line) were transfected with &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;pAdenoVator-Sur-P-NDRG2-IRES-GFP&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;, &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;pAdenoVator-CMV-NDRG2-IRES-GFP&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;, or mock plasmids. Tumor specificity of &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Sur-P &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;was evaluated using fluorescent microscopy for GFP expression. The effects of &lt;em&gt;NDRG2&lt;/em&gt; overexpression on cell viability, apoptosis, and migration of A549 cells were measured using MTT, annexinV/7-AAD flow cytometry, and &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;transwell migration assay, respectively. &lt;/span&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;NDRG2&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; and matrix metalloproteinase-2 (&lt;em&gt;MMP-2&lt;/em&gt;) expression&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;were measured using real time- PCR.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:12pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Results: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;pAdenoVator-Sur-P-NDRG2-IRES-GFP&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; transfection &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;resulted in a huge GFP expression in A549 cells, but not in LX-2 cells. The results of real time-PCR analysis also showed that &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;pAdenoVator-Sur-P-NDRG2-IRES-GFP&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; transfection led to an abundant &lt;em&gt;NDRG2&lt;/em&gt; expression in A549 cells. &lt;em&gt;NDRG2&lt;/em&gt; overexpression decreased A549 cell viability through increasing cell apoptosis. In addition, migration, invasion, and &lt;em&gt;MMP-2&lt;/em&gt; expression decreased following &lt;em&gt;NDRG2&lt;/em&gt; overexpression in A549 cells. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:13pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Conclusion: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;The findings indicate that the targeted overexpression of &lt;em&gt;NDRG2&lt;/em&gt; using &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Sur-P can reduce the viability and invasiveness of A549 cells, suggesting possible benefits of this approach in lung cancer therapy.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
